As TrialSite has reported, there are growing concerns around vaccine safety and the number of adverse events that are occurring soon after the administration of the jab. The majority of these reported adverse events (AEs) are occurring after the second jab. This begs the question: why are the mRNA vaccines following a two-shot regimen? One would assume this decision was based on compelling efficacy data accumulated from the large Phase 3 trial. TrialSite posits below that the data was presented in such a way so that a two-dose regimen was deemed necessary, regardless of risk to patient. The consequence: a mounting safety crisis that could have been avoided with one dose. The data reveals that the one-shot regimen would suffice but the way the efficacy data was represented, the two-shot regimen became the apparent necessity.
Looking at the data from Pfizer's Phase 3 trial, it becomes apparent that they reported a 94.6% relative risk reduction (aka: Vaccine Efficacy) for their two-dose regimen but only a 52.4% relative risk reduction for their single-dose regimen.
From that data, it seems clear that the two-dose regimen confers far superior protection and makes the choice b...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).